BioCentury
ARTICLE | Clinical News

Medivir delays remetinostat Phase III

June 22, 2018 5:57 PM UTC

Medivir AB (SSE:MVIR B) lost SEK4.60 (12%) to SEK34.05 on June 18 after announcing it will delay to 2019 the start of a Phase III trial of remetinostat in early stage cutaneous T-cell lymphoma (CTCL). The company, which had previously guided that the trial would start this year, said the delay is due to continuing discussion with FDA on the trial’s design.

Remetinostat is a topical gel formulation of a tissue-targeted histone deacetylase (HDAC) inhibitor...

BCIQ Company Profiles

Medivir AB

BCIQ Target Profiles

Histone deacetylase (HDAC)